Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) ( · people with primary biliary cholangitis
It is very uncertain whether D‐Penicillamine changes serious adverse events (proportion) ( compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events ‐ delayed or non‐union · adults with olecranon fractures
It is very uncertain whether plate fixation changes adverse events ‐ delayed or non‐union compared with tension band wiring (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events ‐ not measured · patients with acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events ‐ Calcium > 11.5 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events: Shoulder complications · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
Diarrhoea · first aid in patients with acute oral poisoning (toxic berries)
Syrup of ipecac may leads to higher incidence of adverse events: diarrhoea compared with no intervention (low certainty).
1 finding from 1 review
Intervention not reported
Harms or adverse events ‐ not reported · patients and carers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ Phosphate > 7.0 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Adverse events other than hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Adverse events other than hypoglycaemia
It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Adverse events other than hypoglycaemia
It is very uncertain whether DPP‐4 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Adverse events other than hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported